Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part and have given written consent to participate
• People aged 18 or older, of any gender
• People who have been confirmed through tissue or cell testing to have limited-stage small cell lung cancer (meaning the cancer has not spread to distant parts of the body), and who have had brain and bone scans done if spread to those areas was suspected
• People who have immunohistochemistry test results available (a type of lab test done on cancer tissue)
• People whose planned chemotherapy includes either cisplatin or carboplatin, combined with etoposide
• People with a good general physical functioning level (rated 0 or 1 on a standard medical scale, meaning fully active or able to carry out light activity)
• People who weigh more than 40 kg
• People whose doctors expect them to live for at least 6 months
• People who have at least one measurable tumour area (not previously treated with radiation) that is large enough to be accurately measured by CT or MRI scan
• People who have not previously received any immunotherapy
• People whose blood counts, liver, kidney, heart, lung, and clotting functions are all within acceptable ranges as determined by lab tests (confirm specific values with trial site)
• Women who are either post-menopausal or who have had a negative pregnancy test before joining

Who may not be able to join:

• People whose cancer has spread to distant organs (not counting lymph nodes just above the collarbone)
• People who have previously had radiation treatment to the chest
• People who have medical reasons why they cannot receive etoposide combined with carboplatin or cisplatin chemotherapy
• People who have an active autoimmune disease, or a history of one (such as lung inflammation, eye inflammation, bowel inflammation, liver inflammation, or thyroid conditions that are not well controlled), or who have used immune-suppressing medicines in the past 28 days
• People who have previously received or are currently receiving a type of immunotherapy that targets PD-1 or PD-L1, or who are currently taking part in another treatment-based clinical trial
• People who have received other cancer treatments, long-term immune or hormone therapies (other than standard replacement therapies), or experimental treatments within 4 weeks before starting the trial
• People with serious uncontrolled heart problems, such as significant heart failure, unstable chest pain, a heart attack within the past year, or serious irregular heart rhythms requiring medical treatment
• People with immune system deficiencies (such as HIV), active hepatitis B or C, or active tuberculosis
• People who have had an active infection or an unexplained fever above 38.5°C within 2 weeks before screening (though fever caused by the tumour itself may be assessed individually by the trial team)
• People who, in the trial doctor's judgement, have other serious conditions (including mental health conditions) or personal circumstances that could affect their safety or the reliability of the trial data

Important: Always verify eligibility with the trial site directly before applying.